Siemens Healthineers unveiled its midterm financial targets at a Capital Markets Day in London, projecting 5-7% sales compound annual growth rate (CAGR) and double-digit percentage earnings per share CAGR for the period 2027-2030. The company’s shares fell 1% following the announcement.

The healthcare technology firm reported that improvements in its Diagnostics division are progressing toward midterm targets of mid-single-digit percentage sales CAGR and mid-teens EBIT margin. Management indicated openness to strategic options for this business unit.

Siemens Healthineers introduced a new revenue categorization system to support what it calls a “synergistic core.” As part of this structure, the Precision Therapy segment is expected to deliver high-single-digit percentage growth and 100 basis points of margin expansion annually.

Regarding capital allocation, the company mentioned share buybacks as a potential strategy, though this would be implemented in the midterm rather than in 2026.